n/a
Article Publish Status: FREE
Abstract Title:

Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.

Abstract Source:

J Biol Chem. 2013 Nov 22 ;288(47):33542-58. Epub 2013 Oct 2. PMID: 24089526

Abstract Author(s):

Shanshan Pei, Mohammad Minhajuddin, Kevin P Callahan, Marlene Balys, John M Ashton, Sarah J Neering, Eleni D Lagadinou, Cheryl Corbett, Haobin Ye, Jane L Liesveld, Kristen M O'Dwyer, Zheng Li, Lei Shi, Patricia Greninger, Jeffrey Settleman, Cyril Benes, Fred K Hagen, Joshua Munger, Peter A Crooks, Michael W Becker, Craig T Jordan

Article Affiliation:

Shanshan Pei

Abstract:

The development of strategies to eradicate primary human acute myelogenous leukemia (AML) cells is a major challenge to the leukemia research field. In particular, primitive leukemia cells, often termed leukemia stem cells, are typically refractory to many forms of therapy. To investigate improved strategies for targeting of human AML cells we compared the molecular mechanisms regulating oxidative state in primitive (CD34(+)) leukemic versus normal specimens. Our data indicate that CD34(+) AML cells have elevated expression of multiple glutathione pathway regulatory proteins, presumably as a mechanism to compensate for increased oxidative stress in leukemic cells. Consistent with this observation, CD34(+) AML cells have lower levels of reduced glutathione and increased levels of oxidized glutathione compared with normal CD34(+) cells. These findings led us to hypothesize that AML cells will be hypersensitive to inhibition of glutathione metabolism. To test this premise, we identified compounds such as parthenolide (PTL) or piperlongumine that induce almost complete glutathione depletion and severe cell death in CD34(+) AML cells. Importantly, these compounds only induce limited and transient glutathione depletion as well as significantly less toxicity in normal CD34(+) cells. We further determined that PTL perturbs glutathione homeostasis by a multifactorial mechanism, which includes inhibiting key glutathione metabolic enzymes (GCLC and GPX1), as well as direct depletion of glutathione. These findings demonstrate that primitive leukemia cells are uniquely sensitive to agents that target aberrant glutathione metabolism, an intrinsic property of primary human AML cells.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.